Implementation of DAAs in clinical management | Mark Nelson, MD

Andean Pacific Workshop on HIV & Hepatitis 2017

Local situation in LA (epidemiology / treatment options) | Jorge Contreras, MD

Andean Pacific Workshop on HIV & Hepatitis 2017

Early diagnosis & testing | Susana Cabrera, MD

Andean Pacific Workshop on HIV & Hepatitis 2017

Clinical Implications of low level viremia/ failure and resistance | Francesca Ceccherini– Silberstein, PhD

Andean Pacific Workshop on HIV & Hepatitis 2017

Difficult to reach populations in Latin America | Ana Paulina Celi de la Torre, MD

Andean Pacific Workshop on HIV & Hepatitis 2017

WHO Target 90-90-90 : Achievable for Latin America | Alejandro Afani, MD

Andean Pacific Workshop on HIV & Hepatitis 2017

HIV in Latin America: 35 years later | Marcelo Wolff, MD, FACP, FIDSA

Andean Pacific Workshop on HIV & Hepatitis 2017

Benefits of data collaboration – personalized tailoring regimens | Rada Savic, PharmD, PhD

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2017

A Cardiac Risk Algorithm to Predict the Probability of Drug-Induced Torsades de Pointes with Novel Anti-TB Agents | Alexander Berg, PharmD, PhD, FCP

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2017

Searching for a Universal Regimen for Tuberculosis Treatment with a Shorter Duration of Therapy | Khisi Mdluli, PhD

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2017

Prospects for cure | Annemarie Wensing, MD, PhD

European Meeting on HIV & Hepatitis 2018

What is the place of the monoclonal antibodies in the clinic | Julià Blanco, PhD

European Meeting on HIV & Hepatitis 2018

Reduced drug regimens | Andrea De Luca, MD

European Meeting on HIV & Hepatitis 2018

What’s in the pipeline? Presentations by scientists from the industry | Jean-Marc Steens, MD

European Meeting on HIV & Hepatitis 2018

What’s in the pipeline? Presentations by scientists from the industry | Jean-Marc Steens, MD

European Meeting on HIV & Hepatitis 2018

What’s in the pipeline? Presentations by scientists from the industry | Kathleen Squires, MD

European Meeting on HIV & Hepatitis 2018

What’s in the pipeline? Presentations by scientists from the industry | Kathleen Squires, MD

European Meeting on HIV & Hepatitis 2018

Management of hepatitis C therapy failures - clinical perspective | Sanjay Bhagani, BSc FRCP

European Meeting on HIV & Hepatitis 2018

Management of hepatitis C therapy failures - virological perspective | Francesca Ceccherini– Silberstein, PhD

European Meeting on HIV & Hepatitis 2018

Novel simplified bioinformatics for NGS data analysis | Marc Noguera-Julian, PhD

European Meeting on HIV & Hepatitis 2018

New technologies reaching the clinic | Martin Däumer, MSc

European Meeting on HIV & Hepatitis 2018

Implications for clinical practice | Jonathan Schapiro, MD

European Meeting on HIV & Hepatitis 2018

Clinical trial data 3 vs 2 drug regimens | Andrea De Luca, MD

European Meeting on HIV & Hepatitis 2018

Influence of resistance in the future | Richard Harrigan, MD

European Meeting on HIV & Hepatitis 2018